Simpler Grants.gov #HT942526PRMRPTTDA

Army Peer Reviewed Medical Research Program Technology/Therapeutic Development Award Solicitation

This opportunity from the U.S. Army Medical Research Acquisition Activity supports translational medical research for military health needs. - Government Buyer: - U.S. Army Medical Research Acquisition Activity (USAMRAA) - Congressionally Directed Medical Research Programs (CDMRP) - Funding Details: - Approximately $67.2 million available - About 12 awards anticipated - Maximum award cap: $5.6 million per project - Up to 4 years period of performance - Products/Services Requested: - Translational research advancing proof-of-concept or prototype products - Includes drugs, medical devices, clinical decision-making tools, practice guidelines - Focus on preclinical development leading to regulatory filing or clinical practice translation - Unique Requirements: - Research must address health care needs of military Service Members, Veterans, and Families - Must align with FY26 PRMRP topic areas and strategic goals - Applicants must be registered in SAM.gov, eBRAP.org, and Grants.gov - OEMs and Vendors: - No specific OEMs or vendors named; applicants are unrestricted - Place of Performance: - USAMRAA federal office

Description

The fiscal year 2026 (FY26) Peer Reviewed Medical Research Program (PRMRP) Technology/Therapeutic Development Award supports the translation of promising preclinical findings into products for clinical applications related to congressionally directed FY26 PRMRP topic areas and strategic goals. Products may include drugs, devices, clinical decision-making tools, or practice guidelines, addressing health care needs of military Service Members, Veterans, and their Families. The program expects research to advance an established proof-of-concept or prototype through final preclinical development stages, aiming for regulatory filing or clinical practice translation. Approximately $67.2 million is allocated to fund about 12 awards, each with a total cost cap of $5.6 million and a maximum performance period of 4 years.

View original listing